

**Identification of antischistosomal leads by evaluating peroxides of  $\beta$ -dicarbonyl compounds and their heteroanalogs: bridged 1,2,4,5-tetraoxanes, alphaperoxides and  $\beta,\delta$ -triketones: tricyclic monoperoxides**

Katrin Ingram<sup>1,2</sup>, Ivan A. Yaremenko<sup>3</sup>, Igor B. Krylov<sup>3</sup>, Lorenz Hofer<sup>1,2</sup>, Alexander O. Terent'ev<sup>3</sup>, Jennifer Keiser<sup>1,2\*</sup>

<sup>1</sup> *Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, P.O. Box, CH-4002 Basel, Switzerland*

<sup>2</sup> *University of Basel, P.O. Box, CH-4003 Basel, Switzerland*

<sup>3</sup> *N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky prosp., 119991 Moscow, Russian Federation*

\*Corresponding author: Jennifer Keiser, Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Tel.: +41 61 284-8218; Fax: +41 61 284-8105; E-mail: [jennifer.keiser@unibas.ch](mailto:jennifer.keiser@unibas.ch)

## ABSTRACT

Although antischistosomal properties of peroxides were studied in recent years, systematic structure-activity relationships have not been conducted. We evaluated the antischistosomal potential of 64 peroxides belonging to bridged 1,2,4,5-tetraoxanes, alphasperoxides and  $\beta,\delta$ -triketones.

Thirty-nine compounds presented  $IC_{50}$  values  $< 15 \mu M$  on newly transformed schistosomula. Active drugs featured phenyl-, adamantane- or alkyl residues at the methylene bridge. Lower susceptibility was documented on adult schistosomes, with most hit compounds being tricyclic monoperoxides ( $IC_{50}$ : 7.7-13.4  $\mu M$ ). A bridged 1,2,4,5-tetraoxane characterized by an adamantane residue showed the highest activity ( $IC_{50}$ : 0.3  $\mu M$ ) on adult *Schistosoma mansoni*. Studies with hemin and heme supplemented medium indicated that antischistosomal activation of peroxides is not necessarily triggered by iron porphyrins. Two compounds (tricyclic monoperoxide; bridged 1,2,4,5-tetraoxane) revealed high worm burden reductions in the chronic (WBR: 75.4-82.8 %) but only moderate activity in the juvenile (WBR:18.9-43.1%) *S. mansoni* mouse model. Our results might serve as starting point for the preparation and evaluation of related derivatives.

## INTRODUCTION

Schistosomiasis remains one of the most prevalent parasitic diseases, being endemic in 76 countries worldwide with approximately 780 million people at risk of infection.<sup>1</sup> The infection is caused by trematodes of the genus *Schistosoma*, among which *Schistosoma mansoni*, *S. haematobium* and *S. japonicum* represent the most important pathogenic species for humans. During chronic infections worms persist in the liver and hepatic portal system or urinary tract system, depending on the species. Mature schistosomes start laying eggs within their habitation, which often get trapped in the tissues resulting in inflammatory and obstructive diseases of affected organs.<sup>2</sup> In order to cure subtle morbidity and prevent the development of severe late stage morbidity at risk populations are periodically treated with praziquantel, the drug of choice for treating schistosomiasis.<sup>3</sup> Following the discovery of the antischistosomal properties of the artemisinins, in recent years various compounds characterized by a peroxidic scaffold were studied in detail for their antischistosomal activity. The overarching goal of these studies was to identify a drug with high activity against both, juvenile and adult schistosomes. In contrast to praziquantel, the artemisinins revealed high activities against juvenile schistosomes but low to moderate activities on the adult worms in *S. mansoni* infected mice.<sup>4,5</sup> Studies with fully synthetic compounds including ozonides<sup>6,7</sup>, trioxaquinines<sup>8</sup> and dioxolanines<sup>9</sup> were undertaken. In more detail, amongst the aryl-ozonides OZ418 was identified as the most promising lead candidate possessing high activity on both juvenile and adult schistosome infections in mice.<sup>6</sup> The trioxaquinine lead candidate PA1259, a hybrid drug containing an aminoquinoline so as trioxane pharmacophore, was characterized by moderate in vivo activity on juvenile and adult *S. mansoni* in mice.<sup>8,10</sup> In another study a praziquantel-ozonide hybrid was designed, which however failed to demonstrate in vivo activity.<sup>11,12</sup> Finally, the relationship between the peroxidic scaffold and antischistosomal activity was underscored testing a series of alkoxydioxolanines in vitro and in vivo.<sup>9</sup>

However, despite the evaluation of several peroxidic compound classes for their effect on schistosomes, only little is known on the relationship between the peroxidic structures and antischistosomal activity.

Therefore we were interested in elucidating the antischistosomal potential of three practically new peroxide classes, namely bridged 1,2,4,5-tetraoxanes, tricyclic monoperoxides and alphaperoxides in vitro and in vivo against *S. mansoni* for the first time. Bridged 1,2,4,5-tetraoxanes present with a methylene bridge within the pharmacophore which distinguishes them from described 1,2,4,5-tetraoxanes with known trematocidal activity.<sup>13</sup> The preparation of these peroxide classes has been developed recently and their syntheses imply high yields using inexpensive and accessible reagents.<sup>14-17</sup> A library with small drug like molecules showing high structural variability was synthesized for each class of compounds and tested in vitro on Newly Transformed Schistosomula (NTS) and adult *S. mansoni*. The antischistosomal activity of selected compounds was additionally studied in the presence of hemin and heme, as possible activators. Compounds revealing high activity in vitro were next tested on toxicity and further characterized in vivo using a patent *S. mansoni* mouse model. Finally, compounds being active in the chronic infection model progressed into the juvenile infection model to characterize the full spectrum of activity of these peroxides.

## RESULTS

**In vitro screening on NTS.** In a first step the four compound libraries consisting of 27 tetraoxanes, 19 tricyclic monoperoxides, 17 alphaperoxides and one 2-(1-adamantylperoxy)-tetrahydrofuran (Table 1) were tested on *S. mansoni* NTS. Our workflow is presented in Figure 1. Results are summarized in Table 2. Thirty-nine compounds (24 tetraoxanes, 9 tricyclic monoperoxides and 6 alphaperoxides) showed high activities (as defined by half-maximal inhibitory concentrations ( $IC_{50}$ 's)  $\leq 15 \mu\text{M}$ ) on NTS. In more detail, 24 tetraoxanes (89%) revealed  $IC_{50}$  values ranging from 0.1- 13.9  $\mu\text{M}$ . Six of these had  $IC_{50}$  values even lower than 1  $\mu\text{M}$  with compounds **18** ( $IC_{50}$ : 0.1  $\mu\text{M}$ ) and **19** ( $IC_{50}$ : 0.2  $\mu\text{M}$ ) displaying the highest activity. Hence the most active tetraoxanes showed at least 10-fold increased activity when compared to reference drug praziquantel ( $IC_{50}$ : 2.2  $\mu\text{M}$ ) and 25-fold increase in activity when compared to artesunate ( $IC_{50}$ : 5.0  $\mu\text{M}$ ) on the schistosomular stage. The remaining three of the 27 tetraoxanes tested

(compounds **42-44**) showed low to moderate activity ( $IC_{50}$ 's: 15.3 - 58.1  $\mu$ M). Compound **45** was the most active compound in the class of tricyclic monoperoxides ( $IC_{50}$ : 1.7  $\mu$ M). Eight tricyclic monoperoxides had  $IC_{50}$  values ranging from 3.5 to 14.4  $\mu$ M. The remaining compounds showed low to moderate activity ( $IC_{50}$ 's: 15.6-213.2  $\mu$ M compounds **54-60**) or lacked activity (**61-63**) (motility decreased less than 50 % at the highest concentration tested). Of the 17 alphaperoxides tested six compounds (**6,7,9,13-14,17**) were highly active ( $IC_{50}$ 's: 3.9 -14.6  $\mu$ M), eight molecules showed low to moderate activities ( $IC_{50}$ 's 15.1- 293.0  $\mu$ M) and three compounds lacked activity (compound **1,2,5**). Finally the tested 2-(1-adamantylperoxy)-tetrahydrofuran (compound **64**) lacked activity on the schistosomular stage.

**In vitro screening on adult schistosomes.** Thirty-nine compounds progressed into the adult *S. mansoni* screens (Table 2). Of these, six compounds (1 tetraoxane, 4 tricyclic monoperoxides and 1 alphaperoxide) showed high activity (defined as  $IC_{50}$ 's < 15  $\mu$ M) against adult *S. mansoni*. The highest activity was observed with tetraoxane **18** characterized by an  $IC_{50}$  of 0.3  $\mu$ M, revealing comparable in vitro activity as the reference drug praziquantel ( $IC_{50}$ : 0.08  $\mu$ M). The two tricyclic monoperoxides (**51** and **45**) presented  $IC_{50}$  values of 7.7 and 8.7  $\mu$ M, respectively. Compounds **12** (alphaperoxide), **49** and **53** (tricyclic monoperoxides) revealed similar  $IC_{50}$  values of 14.7, 12.2 and 11.7  $\mu$ M respectively.

Twenty-two compounds (16 tetraoxanes, 2 tricyclic monoperoxides and 4 alphaperoxides) showed a low to moderate activity ( $IC_{50}$ 's: 18.8- 132.4  $\mu$ M). Finally, of the 39 compounds tested 11 revealed no decrease of motility of more than 50% on adult *S. mansoni* at the highest concentration tested.

All compounds which revealed a high antischistosomal potential on NTS ( $IC_{50}$  < 5.0  $\mu$ M) but only low, moderate or no activity against adult schistosomes (12 tetraoxanes, 2 tricyclic monoperoxide and 1 alphaperoxide) were retested in the presence of Fe (III)-hemin. In addition, four of these compounds were also studied in a Fe(II) –heme supplemented media.

Selected compounds of alphaperoxides (**11**) and tricyclic monoperoxides (**46**) did not show a great difference in their  $IC_{50}$  values when incubated with (**46**: 92.2  $\mu$ M and **11**: 17.9  $\mu$ M) or without (**46**: >123

$\mu\text{M}$  and **11**: 19.3  $\mu\text{M}$ ) hemin. Similar patterns were also observed for the thirteen tested tetraoxanes. The majority (9 compounds **19,20, 22-25, 27, 29-30**) showed comparable antischistosomal activity with or without hemin or slightly decreased activity (**21, 26, 28** and **31**). A considerable increase of activity was detected for one of the selected tricyclic monoperoxide, compound **47**, lacking activity ( $>103 \mu\text{M}$ ) without and showing an  $\text{IC}_{50}$  value of 14.4  $\mu\text{M}$  with additional hemin. Finally, in the presence of a Fe(II) – heme supplemented media three compounds still lacked activity (**30, 46, 47**) and only one showed a slight increase in activity (**29**;  $\text{IC}_{50}$ :33.6  $\mu\text{M}$ ).

**Determination of cytotoxicity.** The eight compounds displaying high activity against adult *S. mansoni* in vitro were first tested on L6-cells for their cytotoxic potential. Artesunate and praziquantel were used as reference drugs, data are summarized in Table 3. The two tricyclic monoperoxides (**47, 49**) and praziquantel showed no cytotoxic potential at the highest concentration tested (30  $\mu\text{g}/\text{ml}$ ). Lowest cytotoxic potential with  $\text{IC}_{50}$  values of 94.4  $\mu\text{M}$  and 58.3  $\mu\text{M}$  were observed for the alphaperoxide **12** and the tricyclic monoperoxide **53**, respectively. The tricyclic monoperoxides, **45** and **51**, revealed similar moderately cytotoxic  $\text{IC}_{50}$  values from 8.2  $\mu\text{M}$  (**46**) to 10.3  $\mu\text{M}$  (**52**). Furthermore both selected tetraoxanes **18** (1.7  $\mu\text{M}$ ) and **25** (2.2  $\mu\text{M}$ ) showed similar cytotoxic effects on L6-cells as observed for artesunate ( $\text{IC}_{50}$ : 1.5  $\mu\text{M}$ ). Selectivity indices ranged from 0.2 for compound **25** to 7.6 for compound **49** (Table 3). Lead candidates (**18, 53**) (based on the in vivo activity results, see below) and artesunate were further investigated on two different human cell lines, namely HeLa and MRC-5. All compounds showed twofold higher effects on the cancer cell line (HeLa) than on the normal cell line (MRC-5). The lowest cytotoxicity was determined for the tricyclic alphaperoxide **53** ( $\text{IC}_{50}$  of 6.0  $\mu\text{M}$  on HeLa and 12.4  $\mu\text{M}$  on MRC-5) followed by artesunate ( $\text{IC}_{50}$  of 3.2  $\mu\text{M}$  on HeLa and 6.8  $\mu\text{M}$  on MRC-5). Tetraoxane **18** showed cytotoxic potential on both cell lines ( $\text{IC}_{50}$  of 0.4  $\mu\text{M}$  on HeLa and 1.2  $\mu\text{M}$  on MRC-5).

**In vivo efficacy on adult *S. mansoni* infection.** Based on their in vitro activity against adult schistosomes ( $\text{IC}_{50}<15 \mu\text{M}$ ) two tetraoxanes (**18, 25**), five tricyclic monoperoxides (**45, 47, 49, 51** and **53**), and one alphaperoxide (**12**) were tested in mice harboring an adult *S. mansoni* infection (Table 4). The

aliphperoxide **12** and tricyclic monoperoxide **47** lacked in vivo activity. Treatment with three of the tricyclic monoperoxides and one of the tetraoxanes resulted in low total worm burden reductions (WBR) ranging from 4.7 – 31.3 % (compound **25**: 5.0 %, compound **45**: 31.3%, compound **49**: 4.7% and compound **51**: 6.5%). Good antischistosomal in vivo activity was observed with tetraoxane **18** and tricyclic monoperoxide **53**. Compound **18** achieved a total and female WBR of 75.4 % ( $p=0.03$ ) and 77.8% ( $p=0.03$ ), respectively. For the tricyclic monoperoxide **53** significant total and female WBR's of 82.8% ( $p=0.02$ ) and 82.9 % ( $p=0.01$ ) respectively were determined.

**In vivo efficacy studies on juvenile *S.mansoni* infection.** Compounds **18** and **53** were tested against juvenile *S. mansoni* in vivo. The tetraoxane showed moderate total and female WBR's of 43.1% and 50%, respectively. Low WBR's were observed with the tricyclic monoperoxide with 18.9% total and 27.3% female WBR's.

## DISCUSSION AND CONCLUSION

In recent years peroxides have played a prominent role in antischistosomal drug discovery and development. Various studies have been conducted ranging from pre-clinical in vitro and in vivo studies as well as clinical trials.<sup>4,8</sup> Nonetheless to date our knowledge is still limited with regard to the structural requirements these molecules need in order to elicit antischistosomal activity. Therefore in the present work three different peroxide classes were screened for their antischistosomal potential.

First, compounds were studied for activity against NTS (Figure 1). Compounds with an activity  $< 15 \mu\text{M}$  against NTS were classified as active and progressed further. Abdulla and colleagues recently described a similar screening workflow, however using a 15 fold lower cut-off of  $1 \mu\text{M}$  to obtain an acceptable hit rate of 10%.<sup>18</sup> On the other hand, Mansour and Bickle noted that schistosome active drugs were best identified in their screen using concentrations of  $10 \mu\text{g/ml}$  (i.e.  $28\text{--}44 \mu\text{M}$ ) in the primary NTS screen.<sup>19</sup> Given the excellent activity of peroxidic drugs against juvenile schistosomes<sup>4,6</sup>, as mentioned in this work an  $\text{IC}_{50}$  value  $< 15 \mu\text{M}$  was selected as cut-off.

Of 64 compounds tested, 39 (60%) showed high in vitro activity against NTS. For the class of tetraoxanes we detected the highest activity against the schistosomular stage (with 89% of compounds being active) whereas within the other two peroxide classes investigated (tricyclic monoperoxides and aliphatic peroxides) less than half of the compounds displayed activity. Most of the active tetraoxanes elucidated activities comparable to praziquantel on this parasite stage. Structural variation was observed among active compounds on schistosomula. However a tendency of structural features among highly active tetraoxanes and tricyclic monoperoxides could be noted. All highly active structures amongst these two groups presented either phenyl- (**20**, **22**, **24-26**, **30**, **31** and **45**), adamantane- (**18**, **23**) or alkyl- (**19**, **21** and **28**) residues at the methylene bridge.

In contrast to results obtained on NTS with nearly all tetraoxanes being active, showed adult *S. mansoni* a lower susceptibility to these drugs with only one tetraoxane (**18**) revealing prominent activity. This compound revealed also high worm burden reductions against *S. mansoni* in vivo. Compound **18** displays an adamantane substitute at the methylene bridge. Early studies with synthetic peroxides in the framework of a collaborative antimalarial discovery project evaluated essential characteristics for a new trioxolane antimalarial drug. It was documented that necessary pharmacokinetic characteristics could be obtained with the spiroadamantane trioxolane pharmacophore.<sup>20</sup> Increased lipophilicity of the adamantane substituted compounds resulted in higher antimalarial activity. In addition, using the same class of compounds as a starting point to search for a fasciocidal synthetic peroxide drug development candidate revealed that the spiroadamantane substructure is an essential part for fasciocidal activity.<sup>21</sup> Contrary to the known active spiroadamantane substructures, compound **18** does not contain a spiro-fragment; the adamantane and tetraoxane parts are joined directly with a C-C bond.

It is interesting to note that the tested 2-(1-adamantylperoxy)-tetrahydrofuran (**64**) did not expose any activity on the schistosomular stage which indicates that not only the presence of an adamantane part determines the antischistosomal activity. Therefore most probably, the key fragment which determines activity is the bridged tetraoxane and adamantane bears a supporting function.



The class of tricyclic monoperoxides revealed the greatest number of hits (n=4) on adult *S. mansoni* in vitro, with compounds **45** and **51** being most active. Three of the active tricyclic monoperoxides (**45**, **51** and **53**) have a phenyl residue next to the peroxidic bond in common. To note, these phenyl-containing peroxides are unusual compounds from the chemical point of view; generally peroxides containing the Ar-C-O-O moiety easily decompose in accordance with heterolytic mechanism by Hock and related reactions.<sup>22,23</sup>

Furthermore the substitution of the bridge of tricyclic monoperoxides seems to affect the activity as observed on the schistosomular stage likewise. Phenyl residues (compound **49**) seem to increase the activity whereas a propargyl substituent results in decreased activity (as seen for compound **48**).

However, amongst the three tested compounds (**45**, **51** and **53**) in vivo only compound **53** achieved a promising WBR of 82.8 %. This might be explained with a higher metabolic stability of the methylether substituted compound.<sup>24</sup>

It is interesting to note that in general adult *S. mansoni* were less affected by the peroxides than NTS. This was particularly striking for the alphasperoxides and as mentioned before for the bridged 1,2,4,5-tetraoxanes. While six alphasperoxides showed a high activity against NTS, only one was active against the adult worms. In a recent study using a random collection of 33 compounds with proven in vitro activity on adult schistosomes and 30 compounds with lacking adult activity, none of the compounds lacking activity on adult worms revealed significant activity on NTS.<sup>19</sup> This finding suggests a superior susceptibility of schistosomula to peroxidic compounds.

Since it was previously proposed that hemin increases the activity of peroxidic structures, as demonstrated for artemether<sup>25,26</sup> additional experiments were conducted using hemin (Fe(III)) as well as heme (Fe(II)) in the incubation medium. Interestingly, only one tricyclic monoperoxide (compound **47**) showed increased in vitro activity in the presence of hemin, likewise there was only one compound (**29**) which elucidated a slightly increased activity in the presence of heme. This moderately increased in vitro activity could be explained by an additional activation of the drug within the medium and not only within

the parasites gut which was proposed as possible interaction site of hemin and artemether for *S. japonicum*.<sup>26</sup> Most of the selected tetraoxanes showed similar to decreased efficacy when incubated with hemin or heme and no changes on the motility were observed in the supplemented media for the selected alhaperoxides. Note that slight fluctuations in IC<sub>50</sub> values based on microscopical readout might be due to differences in sensitivities of worms or the subjective readout used. Nonetheless these results indicate that an antischistosomal activation of peroxides is not necessarily triggered by hemin or heme or at least does not represent the only activator since great variations were not observed for the two tested peroxide classes (alhaperoxides and 1,2,4,5- tetraoxanes) in the different media.

Only low to moderate activity was observed for the two hit candidates, tetraoxane **18** (WBR: 43.1%) and the tricyclic monoperoxide **53** (WBR: 29.1%) against juvenile *S. mansoni* infections in mice which is in contrary to the recently investigated ozonides or the artemisinins.<sup>5,6</sup> Hence, the activity profile of the investigated peroxides is different from previously studied peroxidic compounds, a finding which cannot be explained at the moment.

Interestingly a high cytotoxic potential was observed for artesunate on all tested celllines, which is in accordance to recently shown induction of cell death by artemisinin compounds and cytotoxic observations on HepG2 cells.<sup>27</sup> The activity of peroxides on blood-feeding parasites is most probably dependent on the activation of the endoperoxide bridge by an iron(II) species leading to C-centered radicals, which might be responsible for cytotoxicity.<sup>27-29</sup> Hence, it is not surprising that some of the tested peroxides showed a higher cytotoxic potential on L6 -cells than the non peroxidic reference drug praziquantel. Furthermore it is known that the artemisinins possess cytotoxic potential on various cancer cell lines<sup>30</sup> and apoptotic processes of fast proliferating cells in presence of iron have been described.<sup>27</sup> It is worthwhile stating that the class of alhaperoxides did not show cytotoxic potential at the highest concentration tested. Most of the tricyclic monoperoxides showed none to moderate cytotoxicity, whereas the class of tetraoxanes showed a similar cytotoxic potential as artesunate. With regard to our lead compounds (**18** and **53**) the conducted in vitro cytotoxicity assay on L6 - cells showed that both lead

structures presented adequate selectivity indices when compared to artesunate. However compound **18** elucidated an increased cytotoxic potential compared to artesunate on tested human cell-lines, which has to be kept in mind as potential drawback.

In conclusion, the screening of three peroxides classes identified two interesting hit compounds, tetraoxane **18** and the tricyclic monoperoxide **53**, which both revealed a high activity against adult *S. mansoni* in vivo. On the other hand, no promising activity was detected within the class of alphaperoxides. Our results hint to the fact that an adamantane group represents an important feature for antischistosomal activity. Compounds **18** and **53** might serve as starting candidates for further lead modifications aiming to increase activity on juvenile schistosomes and to lower cytotoxic potential.

## EXPERIMENTAL SECTION

**Drugs and media.** The 63 (**1-63**) compounds belonging to three types of peroxide classes (bridged 1,2,4,5-tetraoxanes, tricyclic monoperoxides and alphaperoxides) illustrated in Table 1 were prepared based upon methods described by Terent'ev and colleagues.<sup>14-17</sup> Additionally a 2-(1-adamantylperoxy)-tetrahydrofuran (**64**), was prepared from 1-adamantylhydroperoxide and 2,3-dihydrofuran as described in the Supporting Information. 1-adamantylhydroperoxide was prepared from 1,3-dehydroadamantane and H<sub>2</sub>O<sub>2</sub> in accordance with Son, V. V. and colleagues.<sup>31</sup> A hemin solution (1.5 mM) was prepared as follows: 50 mg hemin-chloride (Fluka Analytical, Netherlands) was dissolved in 10 ml of 0.1M NaOH and 39.5 ml of PBS (pH = 7.4). A Fe(II) heme solution (1.5 mM) was prepared by addition of 5 mM dithionite (Sigma Aldrich) to the prepared hemin solution, adapted from Barr et al.<sup>32</sup> Praziquantel and artesunate were purchased from Sigma-Aldrich GmbH.

**Synthesis and analytical data for key compounds.** 7-(1-Adamantyl)-1,4-dimethyl-2,3,5,6-tetraoxabicyclo[2.2.1]heptane **18**.<sup>13</sup> A 37% aqueous H<sub>2</sub>O<sub>2</sub> solution (0.353 g, 3.84 mmol) was added to a solution of 3-(1-adamantyl)pentane-2,4-dione (0.3 g, 1.28 mmol) in EtOH (3 mL), the reaction mixture was cooled to 10°C, and a solution of H<sub>2</sub>SO<sub>4</sub> (2 g, 0.02 mol) in EtOH (2 mL) was added with stirring. The

reaction mixture was stirred at 20-25 °C for 1 h. Then CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added. The organic layer was washed with water (2×10 mL), a 5% aqueous NaHCO<sub>3</sub> solution (2×10 mL), and again with water (2×10 mL), dried with Na<sub>2</sub>SO<sub>4</sub>, and filtered. The solvent was removed using a water-jet vacuum pump. Product 7-(1-adamantyl)-1,4-dimethyl-2,3,5,6-tetraoxabicyclo[2.2.1]heptane **18** was isolated by silica gel chromatography with elution by a hexane – ethyl acetate (EA) mixture using the gradient of the latter from 0 to 30%. Product **18** was obtained in 68% yield (0.231 g, 0.87 mmol). White crystals. Mp = 130-131 °C (partially decomposed). R<sub>f</sub> = 0.60 (TLC, hexane: EA, 5:1). <sup>1</sup>H NMR (300.13 MHz, CDCl<sub>3</sub>), δ: 1.63-2.04 (m, 21H), 2.37 (s, 1H). <sup>13</sup>C NMR (75.48 MHz, CDCl<sub>3</sub>), δ: 12.7, 28.3, 33.0, 36.7, 40.6, 66.8, 110.6. Anal. Calcd for C<sub>15</sub>H<sub>22</sub>O<sub>4</sub>: C, 67.64; H, 8.33. Found: 67.37; H, 8.61.

*3-(4-Methoxyphenyl)-6,7a-dimethyltetrahydro-3H,4H-3,6-epoxy[1,2]dioxolo[3,4-b]pyran* **53**.<sup>16</sup> A 37% aqueous H<sub>2</sub>O<sub>2</sub> solution (0.158 g, 1.72 mmol) and a solution of H<sub>2</sub>SO<sub>4</sub> (1.0 g, 0.01 mol) in EtOH (1 mL) were added with stirring to a solution of 3-(4-methoxybenzoyl)heptane-2,6-dione (0.30 g, 1.14 mmol) in EtOH (4 mL) at 10–15 °C. The reaction mixture was stirred at 20–25 °C for 1 h, and a mixture of CH<sub>2</sub>Cl<sub>2</sub>: hexane = 1:1 (10 mL) was added. Then NaHCO<sub>3</sub> was added to the reaction mixture with stirring until the pH reached 7.0. The precipitate was filtered off. The filtrate was dried over Na<sub>2</sub>SO<sub>4</sub>, the precipitate was filtered off, and the solvent was removed in a water jet vacuum. Product 3-(4-methoxyphenyl)-6,7a-dimethyltetrahydro-3H,4H-3,6-epoxy[1,2]dioxolo[3,4-b]pyran **53** was isolated by chromatography on SiO<sub>2</sub> using a hexane – ethyl acetate mixture as the eluent with a gradient of ethyl acetate from 5 to 50 vol %. Product **53** was obtained in 41% yield (0.131 g, 0.47 mmol). White crystals. Mp = 89–90 °C. R<sub>f</sub> = 0.52 (TLC, hexane:EA, 2:1). <sup>1</sup>H NMR (300.13 MHz, CDCl<sub>3</sub>): δ 1.55 (s, 3H), 1.61 (s, 3H), 1.68–1.80 (m, 4H), 2.62–2.66 (m, H), 3.80 (s, 3H), 6.90 (d, 2H, J = 8.8 Hz), 7.49 (d, 2H, J = 8.8 Hz). <sup>13</sup>C NMR (75.48 MHz, CDCl<sub>3</sub>): δ 12.5, 17.9, 24.8, 29.3, 50.5, 55.3, 95.8, 105.6, 106.5, 113.9, 124.7, 128.1, 160.5. Anal. Calcd for C<sub>15</sub>H<sub>18</sub>O<sub>5</sub>: C, 64.74; H, 6.52. Found: C, 64.73; H, 6.75. HRMS (ESI) m/z [M + H]<sup>+</sup> calcd for [C<sub>15</sub>H<sub>19</sub>O<sub>5</sub>]<sup>+</sup> 279.1227; found 279.1227.

**Instrumentation and Methods.** NMR spectra of novel compounds were recorded on a commercial instrument (300.13 MHz for  $^1\text{H}$ , 75.48 MHz for  $^{13}\text{C}$ ) in  $\text{CDCl}_3$ . The TLC analysis was carried out on standard silica gel chromatography plates. The melting points were determined on a Kofler hot-stage apparatus. Chromatography was performed on silica gel (63-200 mesh). Elemental analysis on carbon, hydrogen, and nitrogen was carried out using a 2400 Perkin-Elmer CHN Analyzer. Determination of purity of all peroxides was executed by elemental (combustion) analysis. For all peroxides deviation from the theoretical values for C, H, and N content was less than 0.4%. These data confirm >95% purity of compounds **1-64**. Structures of all compounds were confirmed using  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra.

**Maintenance of mice and infection with *S. mansoni*.** The in vivo studies were approved by the veterinary authorities of the Canton Basel-Stadt. Female NMRI mice (3-week old, weight ca. 14 g) were purchased from Charles River (Sulzfeld, Germany) or Harlan Laboratories (Horst, the Netherlands). Prior infection, animals were allowed to adapt for one week under controlled conditions (temperature ca. 22 °C; humidity ca. 50 %; 12-hour light and 12-hour dark cycle; free access to rodent diet and water). Mice were infected with *S. mansoni* (Liberian strain) by subcutaneous injection of ~100 cercariae. Cercariae were harvested from infected intermediate host snails *Biomphalaria glabrata* by exposure to light for 3 hours, following standard procedures of our laboratory.

**In vitro compound screening on *S.mansoni* NTS.** Harvested *S. mansoni* cercariae were mechanically transformed to NTS following standard procedures.<sup>33,34</sup> The obtained NTS suspension was adjusted to a concentration of 100 NTS per 50  $\mu\text{l}$  using Medium 199 (Invitrogen, Carlsbad, CA) supplemented with 5% heat-inactivated fetal calf serum (iFCS), 100 U/ml penicillin and 100  $\mu\text{g/ml}$  streptomycin (Invitrogen, Carlsbad, CA). NTS suspensions were incubated (37°C, 5%  $\text{CO}_2$  in ambient air) for a minimum of 12 to 24 h until usage to ensure completed conversion into schistosomula.<sup>35</sup> On the following day drug dilution series were prepared in 96-flat bottom well-plates (BD Falcon, USA) with concentrations ranging from 0.37 to 90  $\mu\text{g/ml}$  (0.37, 1.1, 3.3, 10, 30, 90  $\mu\text{g/ml}$ ) using supplemented (iFCS and antibiotics) Medium 199. The prepared NTS suspension was then added to each well and plates were incubated at 37°C, 5 %

CO<sub>2</sub>. NTS incubated in the presence of the highest DMSO concentration served as control. NTS were evaluated by microscopical readout (Carl Zeiss, Germany, magnification 80x) with regard to death, changes in motility, viability, and morphological alterations 72 h post drug exposure. Drug effects were evaluated using a viability scale as described recently.<sup>33, 34</sup> Each concentration was tested in duplicate and experiments were performed at least three times. IC<sub>50</sub> values of test compounds were determined as described before.<sup>36</sup> Compounds were defined as highly active with IC<sub>50</sub> values ≤ 15 μM, moderate activity was defined as IC<sub>50</sub> 15-40 μM and low activity for values >40 μM.

**In vitro compound screening on adult *S.mansoni*.** Highly active compounds (IC<sub>50</sub> ≤ 15 μM) on NTS were studied on adult schistosomes (workflow presented in Figure 1). Adult flukes were harvested from the hepatic portal veins and mesenteric veins of infected NMRI mice (7-8 weeks post infection) following standard procedures.<sup>7</sup> Schistosomes were placed in RPMI 1640 culture medium supplemented with 5% iFCS, 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C, 5% CO<sub>2</sub> until usage. Supplemented RPMI 1640 medium and drug stock solutions (10 mg/ml) were used to obtain final test concentrations of 1.1-30 μg/ml (1.1, 3.3, 10, 30 μg/ml) in 24-flat bottom well-plates (BD Falcon, USA) with a final volume of 2 ml. At least three schistosomes of both sexes were next added to each well. Schistosomes incubated in the presence of blank medium supplemented with the highest concentration of DMSO used in the assay served as control. Twenty-four, 48 and 72 h post drug exposure schistosomes were examined phenotypically using the motility scale described before<sup>37</sup> and an inverse microscope (Carl Zeiss, Germany, magnification 80x). Experiments were repeated at least three times and IC<sub>50</sub> values determined.<sup>36</sup>

The IC<sub>50</sub> determination (72 h post drug exposure) for selected compounds was repeated with the addition of hemin (120 μM). Compounds showing high antischistosomal potential on the schistosomular stage (IC<sub>50</sub> ≤ 5 μM) but only moderate, low or no activity on adult schistosomes (without hemin supplementation) were selected for these additional experiments. Experiments were performed and repeated as described above with exception of hemin supplementation (120 μM) during the entire drug

exposure time. Compounds which showed very good activities on NTS ( $IC_{50} \leq 5 \mu M$ ) and lacked activity on adult worms were furthermore tested in Fe(II)-heme (120 $\mu M$ ) supplemented media.

**Determination of cytotoxicity.** The determination of cytotoxicity was performed with L-6 -cells according to a previously reported procedure.<sup>38</sup> Briefly, L-6 cells were seeded in 96-well microtiter plates at a density of  $4 \times 10^4$  cells/ml in RPMI 1640 medium with 10 % fetal bovine serum and L-glutamine (2 mM). Drugs serially diluted three-fold ranging from 0.123 to 30  $\mu g/ml$  in test medium were added. The plates were incubated at 37°C at an atmosphere of 5 % CO<sub>2</sub>. After 70 hours, Alamar Blue® (10  $\mu L$ ) was added to each well and incubation was continued for another 2 hours. The plate was then read using a SpectraMax M2 (MolecularDevices) instrument by use of an excitation wavelength of 530 nm and an emission wavelength of 590 nm. Fluorescence development was expressed as percentage of the control and the  $IC_{50}$  values were determined. Experiments were performed at least three times and  $IC_{50}$  values calculated as averages. The selectivity indices (SI) of tested compounds were calculated by dividing  $IC_{50}$  obtained on L6- cells with  $IC_{50}$  values determined on adult *S. mansoni*.

The cytotoxic potential of 2 lead candidates was additionally determined on human cervical carcinoma cells (HeLa) cells and human fetal Lung fibroblast cells (MRC-5) (see Supporting Information).

**In vivo testing.** Compounds revealing an activity of  $\leq 15 \mu M$  on adult worms post 72 h drug exposure were tested in vivo. Groups of 4 infected NMRI mice characterized by a patent schistosome infection (49 days post infection) were treated orally with the test drug using single oral doses of 400 mg compound per kg body weight. Eight to ten untreated mice served as controls. Fourteen days post-treatment animals were killed by the CO<sub>2</sub> method, dissected and worms were sexed and counted.<sup>7</sup> Worm burdens of treated mice were compared to untreated animals and reductions of worm burden calculated. Compounds displaying high activities against adult *S. mansoni* in vivo were also tested in the juvenile *S. mansoni* mouse model. For that purpose mice were treated with the test compounds 21-days post

infection and killed so as dissected four weeks post treatment. Worm burden reductions were calculated as described above.

**Statistics.** Parasite viability values of treated and untreated NTS and adult schistosomes obtained from sextuplicate evaluation were averaged (means (+/- standard deviation)) using Microsoft Excel software. IC<sub>50</sub> values of test compounds were determined using the CompuSyn software (Version 3.0.1, 2007; ComboSyn, Inc). The Kruskal-Wallis test was applied for in vivo studies, comparing the medians of the worm burden reductions of the treatment and control groups. A difference in median was considered to be significant at a significance level of 5% (StatsDirect statistical software, version 2.7.2.; StatsDirect Ltd., United Kingdom).

## ASSOCIATED CONTENT

### Supporting Information

<sup>1</sup>H and <sup>13</sup>C NMR spectra, data of elemental analysis, and physical state of newly introduced tetraoxanes, structure **64** and cytotoxic potential of lead candidates on human cell-lines. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## AUTHOR INFORMATION

\***Corresponding author:** Jennifer Keiser, Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Tel.: +41 61 284-8218; Fax: +41 61 284-8105; E-mail: [jennifer.keiser@unibas.ch](mailto:jennifer.keiser@unibas.ch)

## Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENTS



We are grateful to SNSF (project no. PPOOA3--114941 and PPOOP3\_135170 to JK), the Scientific & Technological Cooperation Programme Switzerland-Russia, the Grant of the Russian Foundation for Basic Research (Grant 11-03-00857-a), the Program for Basic Research of the Presidium of the Russian Academy of Sciences and the Ministry of Education and Science of the Russian Federation (Grant No. 11.519.11.2038) for financial support We would like to thank Prof. Gilles Gasser, Vanessa Pierroz and Dr. Stefano Ferrari for their expert help with the cytotoxicity studies.

## REFERENCES

- (1) Steinmann, P.; Keiser, J.; Bos, R.; Tanner, M.; Utzinger, J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. *Lancet Infect Dis* **2006**, 6, 411-425.
- (2) Gryseels, B.; Polman, K.; Clerinx, J.; Kestens, L. Human schistosomiasis. *Lancet* **2006**, 368, 1106-1118.
- (3) WHO. Preventive Chemotherapy in Human Helminthiasis. World Health Organisation, Geneva **2006**.
- (4) Utzinger, J.; Xiao, S. H.; Tanner, M.; Keiser, J. Artemisinins for schistosomiasis and beyond. *Curr Opin Investig Drugs* **2007**, 8, 105-116.
- (5) Utzinger, J.; Chollet, J.; Tu, Z.; Xiao, S.; Tanner, M. Comparative study of the effects of artemether and artesunate on juvenile and adult *Schistosoma mansoni* in experimentally infected mice. *Trans R Soc Trop Med Hyg* **2002**, 96, 318-323.
- (6) Keiser, J.; Ingram, K.; Vargas, M.; Chollet, J.; Wang, X.; Dong, Y.; Vennerstrom, J. L. In Vivo Activity of Aryl Ozonides against *Schistosoma* Species. *Antimicrob Agents Chemother* **2012**, 56, 1090-1092.

- (7) Xiao, S. H.; Keiser, J.; Chollet, J.; Utzinger, J.; Dong, Y.; Endriss, Y.; Vennerstrom, J. L.; Tanner, M. In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species. *Antimicrob Agents Chemother* **2007**, 51, 1440-1445.
- (8) Portela, J.; Boissier, J.; Gourbal, B.; Pradines, V.; Colliere, V.; Cosledan, F.; Meunier, B.; Robert, A. Antischistosomal Activity of Trioxaquinines: In Vivo Efficacy and Mechanism of Action on *Schistosoma mansoni*. *PLoS Negl Trop Dis* **2012**, 6, e1474.
- (9) Ingram, K.; Schiaffo, C. E.; Sittiwong, W.; Benner, E.; Dussault, P. H.; Keiser, J. In vitro and in vivo activity of 3-alkoxy-1,2-dioxolanes against *Schistosoma mansoni*. *J Antimicrob Chemother* **2012**.
- (10) Boissier, J.; Cosledan, F.; Robert, A.; Meunier, B. In vitro activities of trioxaquinines against *Schistosoma mansoni*. *Antimicrob Agents Chemother* **2009**, 53, 4903-4906.
- (11) Dong, Y.; Chollet, J.; Vargas, M.; Mansour, N. R.; Bickle, Q.; Alnouti, Y.; Huang, J.; Keiser, J.; Vennerstrom, J. L. Praziquantel analogs with activity against juvenile *Schistosoma mansoni*. *Bioorg Med Chem Lett* **2010**, 20, 2481-2484.
- (12) Duan, W.-w.; Qiu, S.-j.; Zhao, Y.; Sun, H.; Qiao, C.; Xia, C.-m. Praziquantel derivatives exhibit activity against both juvenile and adult *Schistosoma japonicum*. *Bioorg Med Chem Lett* **2012**, 22, 1587-1590.
- (13) Kirchhofer, C.; Vargas, M.; Braissant, O.; Dong, Y.; Wang, X.; Vennerstrom, J. L.; Keiser, J. Activity of OZ78 analogues against *Fasciola hepatica* and *Echinostoma caproni*. *Acta Trop* **2011**, 118, 56-62.
- (14) Terent'ev, A. O.; Borisov, D. A.; Chernyshev, V. V.; Nikishin, G. I. Facile and selective procedure for the synthesis of bridged 1,2,4,5-tetraoxanes; strong acids as cosolvents and catalysts for addition of hydrogen peroxide to beta-diketones. *J Org Chem* **2009**, 74, 3335-3340.
- (15) Terent'ev, A. O.; Borisov, D. A.; Semenov, V. V.; Chernyshev, V. V.; Dembitsky, V. M.; Nikishin, G. I. Selective Synthesis of Unsymmetrical Peroxides: Transition-Metal (Cu, Fe, Mn, Co) -Catalyzed

Oxidation of Derivatives of Malononitrile and Cyanoacetic Ester by tert-Butyl Hydroperoxide at the  $\alpha$ -Position. *ChemInform* **2011**, 13, 2091-2100.

- (16) Terent'ev, A. O.; Borisov, D. A.; Yaremenko, I. A.; Chernyshev, V. V.; Nikishin, G. I. Synthesis of asymmetric peroxides: transition metal (Cu, Fe, Mn, Co) catalyzed peroxidation of beta-dicarbonyl compounds with tert-butyl hydroperoxide. *J Org Chem* **2010**, 75, 5065-5071.
- (17) Terent'ev, A. O.; Yaremenko, I. A.; Chernyshev, V. V.; Dembitsky, V. M.; Nikishin, G. I. Selective synthesis of cyclic peroxides from triketones and H<sub>2</sub>O<sub>2</sub>. *J Org Chem* **2012**, 77, 1833-1842.
- (18) Abdulla, M. H.; Ruelas, D. S.; Wolff, B.; Snedecor, J.; Lim, K. C.; Xu, F.; Renslo, A. R.; Williams, J.; McKerrow, J. H.; Caffrey, C. R. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. *PLoS Negl Trop Dis* **2009**, 3, e478.
- (19) Mansour, N. R.; Bickle, Q. D. Comparison of microscopy and Alamar blue reduction in a larval based assay for schistosome drug screening. *PLoS Negl Trop Dis* **2010**, 4, e795.
- (20) Vennerstrom, J. L.; Arbe-Barnes, S.; Brun, R.; Charman, S. A.; Chiu, F. C. K.; Chollet, J.; Dong, Y.; Dorn, A.; Hunziker, D.; Matile, H.; McIntosh, K.; Padmanilayam, M.; Santo Tomas, J.; Scheurer, C.; Scorneaux, B.; Tang, Y.; Urwyler, H.; Wittlin, S.; Charman, W. N. Identification of an antimalarial synthetic trioxolane drug development candidate. *Nature* **2004**, 430, 900-904.
- (21) Zhao, Q.; Vargas, M.; Dong, Y.; Zhou, L.; Wang, X.; Sriraghavan, K.; Keiser, J.; Vennerstrom, J. L. Structure-activity relationship of an ozonide carboxylic acid (OZ78) against *Fasciola hepatica*. *J Med Chem* **2010**, 53, 4223-4233.
- (22) Hock, H.; Lang, S. Autoxydation von Kohlenwasserstoffen, IX. Mitteil.: Über Peroxyde von Benzol-Derivaten. *Berichte der deutschen chemischen Gesellschaft (A and B Series)* **1944**, 77, 257-264.
- (23) Nakamura, R.; Obora, Y.; Ishii, Y. Selective one-pot synthesis of various phenols from diarylethanes. *Chem Commun* **2008**, 3417-3419.

- (24) Ferriz, J. M.; Vinsova, J. Prodrug design of phenolic drugs. *Curr Pharm Des* **2010**, *16*, 2033-2052.
- (25) Xiao, S.; Chollet, J.; Utzinger, J.; Matile, H.; Mei, J.; Tanner, M. Artemether administered together with haemin damages schistosomes in vitro. *Trans R Soc Trop Med Hyg* **2001**, *95*, 67-71.
- (26) Xiao, S. H.; Wu, Y. L.; Tanner, M.; Wu, W. M.; Utzinger, J.; Mei, J. Y.; Scorneaux, B.; Chollet, J.; Zhai, Z. *Schistosoma japonicum*: In vitro effects of artemether combined with haemin depend on cultivation media and appraisal of artemether products appearing in the media. *Parasitol Res* **2003**, *89*, 459-466.
- (27) Mercer, A. E.; Maggs, J. L.; Sun, X. M.; Cohen, G. M.; Chadwick, J.; O'Neill, P. M.; Park, B. K. Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. *J Biol Chem* **2007**, *282*, 9372-9382.
- (28) Meshnick, S. R.; Yang, Y. Z.; Lima, V.; Kuypers, F.; Kamchonwongpaisan, S.; Yuthavong, Y. Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). *Antimicrob Agents Chemother* **1993**, *37*, 1108-1114.
- (29) Robert, A.; Benoit-Vical, F. o.; Claparols, C.; Meunier, B. The antimalarial drug artemisinin alkylates heme in infected mice. *PNAS* **2005**, *102*, 13676-13680.
- (30) Efferth, T.; Sauerbrey, A.; Olbrich, A.; Gebhart, E.; Rauch, P.; Weber, H. O.; Hengstler, J. G.; Halatsch, M.-E.; Volm, M.; Tew, K. D.; Ross, D. D.; Funk, J. O. Molecular Modes of Action of Artesunate in Tumor Cell Lines. *Mol Pharmacol* **2003**, *64*, 382-394.
- (31) Son, V. V.; Ivashchenko, S. P.; Son, T. V. Syntheses based on 1,3-dehydroadamantane *Zhurnal Obshchei Khimii* **1990**, *60*, 710-712.
- (32) Barr, I.; Smith, A. T.; Chen, Y.; Senturia, R.; Burstyn, J. N.; Guo, F. Ferric, not ferrous, heme activates RNA-binding protein DGCR8 for primary microRNA processing. *Proceedings of the National Academy of Sciences* **2012**.

- (33) Keiser, J. In vitro and in vivo trematode models for chemotherapeutic studies. *Parasitology* **2009**, 137, 589-603.
- (34) Manneck, T.; Haggemuller, Y.; Keiser, J. Morphological effects and tegumental alterations induced by mefloquine on schistosomula and adult flukes of *Schistosoma mansoni*. *Parasitology* **2009**, 137, 85-98.
- (35) Cousin, C. E.; Stirewalt, M. A.; Dorsey, C. H.; Watson, L. P. *Schistosoma mansoni*: comparative development of schistosomules produced by artificial techniques. *J Parasitol* **1986**, 72, 606-609.
- (36) Ingram, K.; Ellis, W.; Keiser, J. Antischistosomal activities of mefloquine-related arylmethanols. *Antimicrob Agents Chemother* **2012**, 56, 3207-3215.
- (37) Ramirez. Schistosomes: challenges in compound screening. *Expert Opin. Drug Discov.* **2007**, 2, 53-61.
- (38) Sperandeo, N. R.; Brun, R. Synthesis and biological evaluation of pyrazolynaphthoquinones as new potential antiprotozoal and cytotoxic agents. *Chembiochem* **2003**, 4, 69-72.

**Table 1**

Chemical structures of investigated structures presented regarding their peroxidic class.





















(\*) Detailed information can be found in supplementary information.

Alphaperoxydes which are $\alpha$ - <i>tert</i> -butylperoxy derivatives of $\alpha$ -substituted 1-17	acetyl acetone <sup>16</sup>						
		<b>1</b>	<b>2</b>				
	acetoacetic ester <sup>16</sup>						
		<b>3</b>	<b>4</b>	<b>5</b>			
		malonic ester <sup>16</sup>					
	<b>6</b>						
	cyanoacetic ester <sup>15</sup>						
		<b>7</b>	<b>8</b>	<b>9</b>	<b>10</b>		
		malono nitrile <sup>15</sup>					
			<b>11</b>	<b>12</b>	<b>13</b>	<b>14</b>	<b>15</b>
	<b>16</b>		<b>17</b>				

Bridged 1,2,4,5-tetraoxanes(\*)<sup>14</sup>

18-44

<b>18</b>	<b>19</b>	<b>20</b>	<b>21</b>	<b>22</b>
<b>23</b>	<b>24</b>	<b>25</b>	<b>26</b>	<b>27</b>
<b>28</b>	<b>29</b>	<b>30</b>	<b>31</b>	<b>32</b>
<b>33</b>	<b>34</b>	<b>35</b>	<b>36</b>	<b>37</b>
<b>38</b>	<b>39</b>	<b>40</b>	<b>41</b>	<b>42</b>
<b>43</b>	<b>44</b>			

Tricyclic monoperoxides <sup>17</sup>  <b>45-63</b>					
	<b>45</b>	<b>46</b>	<b>47</b>	<b>48</b>	<b>49</b>
					
	<b>50</b>	<b>51</b>	<b>52</b>	<b>53</b>	<b>54</b>
					
	<b>55</b>	<b>56</b>	<b>57</b>	<b>58</b>	<b>59</b>
					
<b>60</b>	<b>61</b>	<b>62</b>	<b>63</b>		
2- (1- adamantylperoxy) -tetrahydrofuran (*)  <b>(64)</b>					
	<b>64</b>				



**Table 2**

In vitro activity of 3 different peroxide classes (alphaperoxides, bridged 1,2,4,5-tetraoxanes, and tricyclic monoperoxides) and one 2-(1-adamantylperoxy)-tetrahydrofuran on NTS and *S. mansoni*. R represents the “goodness of fit” whereas >0.85 is acceptable.

Peroxide class	Nr.	NTS		<i>S. mansoni</i>		hemin (120µM)	
		IC <sub>50</sub>	r	IC <sub>50</sub>	r	IC <sub>50</sub>	r
		[µM]		[µM]		[µM]	
Artesunate		4.97	0.9	41.2	0.8	38.7	0.7
Praziquantel		2.2	0.9	0.1	0.9		
alphaperoxides	<b>1</b>	>104					
	<b>2</b>	>795					
	<b>3</b>	15.1	0.9				
	<b>4</b>	26.5	0.9				
	<b>5</b>	>111					
	<b>6</b>	14.6	0.9	59.1	0.8		
	<b>7</b>	9.0	0.9	>126.8			
	<b>8</b>	37.8	0.8				
	<b>9</b>	43.2	0.9				
	<b>10</b>	67.7	1.0				
	<b>11</b>	3.9	0.9	19.3	0.8	17.9	0.9
	<b>12</b>	5.0	0.9	14.7	0.9		
	<b>13</b>	8.0	0.9	40.6	1.0		
	<b>14</b>	10.7	0.9	122.9	0.9		

	<b>15</b>	24.1	0.9				
	<b>16</b>	157.0	0.9				
	<b>17</b>	293.0	0.3				
bridged 1,2,4,5-	<b>18</b>	0.1	0.9	0.3	1.0		
tetraoxanes	<b>19</b>	0.2	1.0	61.5	0.9	27.3	0.9
	<b>20</b>	0.4	0.9	35.5	0.9	25.3	1.0
	<b>21</b>	0.5	1.0	37.8	1.0	>159	
	<b>22</b>	0.6	0.9	30.9	1.0	41.2	0.9
	<b>23</b>	0.8	0.8	33.3	1.0	39.3	1.0
	<b>24</b>	1.0	0.9	33.6	0.9	47.7	0.9
	<b>25</b>	1.1	0.9	18.8	1.0	12.9	0.9
	<b>26</b>	1.2	0.8	40.0	0.9	>127	
	<b>27</b>	1.2	0.8	132.4	0.9	91.9	0.9
	<b>28</b>	3.4	0.9	49.8	0.9	>174	
	<b>29</b>	3.4	0.9	>89.8		>89.8	
	<b>30</b>	4.4	1.0	>112		>112	
	<b>31</b>	5.0	0.9	41.4	0.7	134.9	0.9
	<b>32</b>	5.5	0.9	50.1	0.9		
	<b>33</b>	6.1	1.0	65.6	0.9		
	<b>34</b>	6.6	1.0	>110.6			
	<b>35</b>	7.1	0.8	35.5	1.0		
	<b>36</b>	8.9	0.9	66.6	0.9		
	<b>37</b>	9.8	0.9	>129.2			
	<b>38</b>	10.7	0.9	36.9	0.8		

	<b>39</b>	10.9	0.9	>102		
	<b>40</b>	11.7	0.9	>103.7		
	<b>41</b>	13.9	0.9	>117		
	<b>42</b>	15.3	1.0			
	<b>43</b>	25.6	0.9			
	<b>44</b>	58.1	0.8			
<hr/>						
tricyclic	<b>45</b>	1.7	0.8	8.7	0.9	
monoperoxides	<b>46</b>	3.5	0.9	>105		92.2 0.9
	<b>47</b>	4.5	0.9	>103		13.4 0.9
	<b>48</b>	8.1	1.0	82.4	0.9	
	<b>49</b>	9.0	0.9	12.2	0.8	
	<b>50</b>	9.0	1.0	19.2	0.9	
	<b>51</b>	9.3	0.8	7.7	0.9	
	<b>52</b>	13.4	0.9	>109		
	<b>53</b>	14.4	0.8	11.7	0.9	
	<b>54</b>	15.6	0.9			
	<b>55</b>	16.0	0.9			
	<b>56</b>	22.3	0.9			
	<b>57</b>	22.5	0.8			
	<b>58</b>	45.3	0.9			
	<b>59</b>	180.4	0.9			
	<b>60</b>	213.2	0.9			
	<b>61</b>	>287				
	<b>62</b>	>348				

---

63 >376

---

2-(1- 64 >125.9

adamantylperoxy)-

tetrahydrofuran

---

\*as described by Keiser *et al.* . J Antimicrob Chemother 2011; 66: 1791– 1797

**Table 3**

IC<sub>50</sub> values of eight selected hit compounds (**12**, **18**, **25**, **45**, **47**, **49**, **51** and **53**) evaluated with L6-cells and adult *S. mansoni* worms. Selectivity Indices (SI) were calculated based on evaluated IC<sub>50</sub> values and Artesunate so as Praziquantel served as control compounds.

Compound	IC <sub>50</sub> [μM]		SI
	L6- cells (SD)	<i>S. mansoni</i>	
12	99.0 (11.0)	14.7	6.4
18	1.7 (0.3)	0.3	5.7
25	2.2 (0.4)	18.8	0.1
45	8.2 (1.9)	8.7	0.9
47	> 103	13.4	> 7.7
49	> 93	12.2	> 7.6
51	10.3 (1.8)	7.7	1.3
53	58.3 (17.9)	11.8	4.9
Artesunate	1.5 (0.6)	38.7	0.04
Praziquantel	> 96	0,1	> 960

SD: Standard deviation; SI: Selectivity Index

**Table 4**

*In vivo* activity of selected compounds from 3 different peroxide classes (bridged 1,2,4,5-tetraoxanes, tricyclic monoperoxides, alphaperoxides). All tested on patent adult schistosoma infection (49 days post treatment) and promising candidates as well on juvenile schistosoma infections (21 days post-treatment)

Compound (Chemical class)	Mice investigated	Mean number of worms (SD)		Adult infection [%]		Juvenile infection [%]	
		Total	Females	TWR	FWBR	TWR	FWBR
control <sup>a</sup>	9	29 (28.5)	13.3 (12.9)	-	-	-	-
control <sup>b</sup>	8	38.3 (18.1)	20.6 (8.8)	-	-	-	-
control <sup>c</sup>	10	30.6 (24.7)	16.1 (13)	-	-	-	-
control <sup>d</sup>	8	21.6 (12.2)	11.0 (6.4)	-	-	-	-
<b>12<sup>a</sup></b>	4	32.3 (21.4)	17.3 (11.6)	0.0	0.0		
<b>18<sup>a</sup></b>	6	6.7 (2.5)	2.3 (1.2)	*75.4	*77.8	43.1	50
<b>25<sup>d</sup></b>	2	20.5 (11.5)	10.5 (9.2)	5.0	4.6		
<b>45<sup>c</sup></b>	4	21 (2.2)	10.3 (3.1)	31.3	36.4		
<b>47<sup>d</sup></b>	4	22.3 (4.9)	12 (2.4)	0.0	0.0		
<b>49<sup>d</sup></b>	4	23.5 (5.9)	11.8 (3.1)	4.7	9.6		
<b>51<sup>b</sup></b>	4	35.8 (8.2)	17.5 (6.6)	6.5	15.2		
<b>53<sup>c</sup></b>	4	5.3 (5)	2.8 (2.6)	*82.8	*82.9	18.9	27.3

TWR: Total worm burden reduction; FWBR: Female worm burden reduction; SD: Standard deviation;

\* p-value < 0.05 using KW-Test

## **Figure legends**

### **Figure 1**

Flow chart of our screening procedures using three different peroxide classes and one 2-(1-adamantylperoxy)-tetrahydrofuran.

### **List of nonstandard abbreviations and acronyms**

NTS, newly transformed schistosomula; WBR, worm burden reduction; TWBR, total worm burden reduction; FWBR, female worm burden reduction; SI, selectivity index

## TABLE OF CONTENTS GRAPHIC

